BioCryst Pharmaceuticals, Inc.
BCRX
$9.81
$0.657.10%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 209.09% | 36.14% | 49.41% | 56.89% | 40.83% |
| Total Other Revenue | -- | -- | -- | -- | 191.82% |
| Total Revenue | 209.09% | 36.14% | 49.41% | 56.89% | 40.83% |
| Cost of Revenue | -15.13% | 5.64% | 17.45% | -12.40% | -19.04% |
| Gross Profit | 366.89% | 54.69% | 67.36% | 130.42% | 193.69% |
| SG&A Expenses | 16.53% | 27.52% | 42.67% | 38.62% | 25.64% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.77% | 18.66% | 32.81% | 15.91% | 2.77% |
| Operating Income | 8,321.30% | 284.70% | 239.98% | 246.51% | 91.40% |
| Income Before Tax | 1,054.24% | 190.21% | 151.88% | 102.16% | 58.85% |
| Income Tax Expenses | 170.15% | -231.23% | 714.53% | 98.90% | 156.18% |
| Earnings from Continuing Operations | 1,017.50% | 191.92% | 140.12% | 100.09% | 56.59% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1,017.50% | 191.92% | 140.12% | 100.09% | 56.59% |
| EBIT | 8,321.30% | 284.70% | 239.98% | 246.51% | 91.40% |
| EBITDA | 9,200.27% | 273.93% | 231.63% | 252.01% | 91.87% |
| EPS Basic | 1,001.93% | 190.56% | 139.58% | 100.12% | 57.85% |
| Normalized Basic EPS | 1,152.75% | 208.87% | 183.91% | 102.17% | 58.77% |
| EPS Diluted | 967.28% | 185.71% | 132.57% | 100.06% | 57.80% |
| Normalized Diluted EPS | 1,113.02% | 204.19% | 179.95% | 102.07% | 58.77% |
| Average Basic Shares Outstanding | 1.73% | 1.58% | 1.50% | 1.37% | 2.97% |
| Average Diluted Shares Outstanding | 5.73% | 6.27% | 6.52% | 4.46% | 2.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |